Overview
- 3 public-safe observations are available for this inspection.
- 1 structured CFR citation is represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
15 Jun 2026
FDCA 501(a)(2)(A)
Beta-lactam, hazardous, highly potent drugs, prevention of cross-contamination
Cited by Erik W Koester, Syeda N Mahazabin
15 Jun 2026
FDCA 501(a)(2)(A)
Failure to clean and disinfect/sterilize equipment, ISO 5 area
Cited by Erik W Koester, Syeda N Mahazabin
15 Jun 2026
FDCA 501(a)(2)(A)
Microbial contamination was present, ISO 5/areas adjacent
Cited by Erik W Koester, Syeda N Mahazabin
Inspected site
FVFayetteville VA Medical CenterFayetteville, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| FDCA 501(a)(2)(A) | Cited across public-safe Form 483 observations | 3x |
Full 483 report
Get the verbatim text of all 3 observations
The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere